Essentials of bladder cancer worldwide: incidence, mortality rate and risk factors

Gandomani, Hamidreza Sadeghi; Tarazoj, Abed Asgari; Siri, Fatemeh Hadavand; Rozveh, Ali Karimi; Hosseini, Soheila; Borujeni, Narges Naseri; Mohammadian-Hafshejani, Abdollah; Salehiniya, Hamid

doi:10.15419/bmrat.v4i9.371

Cited by 19 publications

(8 citation statements)

References 71 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to literature, Bulgaria is the only country where males had a significant increase in both incidence and mortality (Wong et al ,2018). In our study, we also established the ratio between man and women was 3.2:1, and the average age of the patients with urothelial carcinoma of the bladder is 70.14 years on average, which is similar to the results of almost all published studies (Horstmann et al, 2008;Gandomani et al, 2017).…”

Section: Discussionsupporting

confidence: 88%

Epidemiological and Morphological Characteristics of Urothelial Bladder Cancer in a Bulgarian and a French Sample of Patients

Gulinac

Dikov

Velikova

2020

aijmsr

View full text Add to dashboard Cite

Bladder carcinoma (BC) is one of the most common malignancies of the urinary system in developed countries, and it is also characterized by a high number of recurrences and progression rates despite multimodal treatment. BC is a biological and clinically heterogeneous tumor with a great propensity of divergent differentiation. Around the world, bladder cancer is responsible for 549.000 new cases и 200.000 deaths each year. In Bulgaria, bladder carcinoma is the 18th most common neoplasia. Our results on 105 proven bladder carcinoma cases confirmed that this tumor arises at 70 years at average (60-90 years), it affects men predominantly and there was no difference regarding the nationality of patients. In conclusion, it remains a diagnostic challenge.

show abstract

Section: Discussionsupporting

confidence: 88%

Epidemiological and Morphological Characteristics of Urothelial Bladder Cancer in a Bulgarian and a French Sample of Patients

Gulinac

Dikov

Velikova

2020

aijmsr

View full text Add to dashboard Cite

show abstract

“…Despite the advances in the treatment of colon cancer in the last decades, the growing death rate is still statistically remarkable in the patients 23 . It was demonstrated that NRF2 is an upstream transcriptional activator of PDL1 which regulates its expression 14 .…”

Section: Discussionmentioning

confidence: 99%

The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells

Payandeh¹,

Tazehkand²,

Mansoori³

et al. 2021

AJMB

View full text Add to dashboard Cite

Background: Nuclear factor-erythroid 2-related factor 2 (Nrf2) plays a key role in promoting chemoresistance in various cancers. PD-L1 is one of the downstream targets of the Nrf2 signaling pathway. This molecule has some beneficial impacts on tumors growth by inhibition of the immune system. This study aimed to investigate the potential role of the Nrf2-PD-L1 axis in the promotion of oxaliplatin resistance in colon cancer cells. Methods: We examined Nrf2, PD- L1, and CD80 expression in the tumor and margin tissue samples from CRC patients. After that role of the Nrf2-PD-L1 axis in promotion of Oxaliplatin resistance was investigated. Results: Our data revealed that Nrf2 and PD-L1 mRNA expressions were markedly higher in tumor tissues compared to margin tissues. The PD-L1 mRNA expression level was also increased in the resistant cells. However, Nrf2 expression was decreased in SW480/Res cells and increased in LS174T/Res cells. The inhibition of Nrf2 through siRNA treatment in SW480/Res and LS174T/Res cells has decreased the IC50 values of oxaliplatin. Inhibition of the Nrf2 has significantly increased the oxaliplatin-induced apoptosis, and reduced the migration in SW480/Res cells. Conclusion: It is suggested that effective inhibition of Nrf2-PD-L1 signaling pathways can be considered as a novel approach to improve oxaliplatin efficacy in colon cancer patients.

show abstract

“…However, few of the genetic prognostic biomarkers for bladder cancer had been developed utilizing their clonal or sub-clonal states in large cohorts of patients with different genetic background, despite of the well-documented disparities in bladder cancer risk and survival across races/ethnics in epidemiological studies 10 . Whites are more than twice likely to develop bladder cancer than Blacks while Asian Americans have lower risk of developing bladder cancer than Whites and Blacks 11 . The clinical outcomes of bladder cancer also exhibit racial disparities with shorter survival observed in Blacks 10 .…”

Section: Introductionmentioning

confidence: 95%

Racial differences in genomic features and new trans-ancestry prognosis subtypes in bladder cancer

Zhang

Jia²,

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

The incidence and survival of bladder cancer vary greatly among different populations but the influence of the associated molecular features and evolutionary processes on its clinical treatment and prognostication remains unknown. Here, we analyze the genomic architectures of over 500 bladder cancer patients from Asian/Black/White populations. We identify novel association between AHNAK mutations and APOBEC-a mutational signature whose activities vary substantially across populations. All significantly mutated genes but only half of arm-level somatic copy number alterations (SCNAs) are enriched with clonal events, indicating large-scale SCNAs as rich sources fostering bladder cancer clonal diversities. The prevalence of TP53 and ATM clonal mutations as well as the associated burden of SCNAs is significantly higher in Whites/Blacks than in Asians. We identify a trans-ancestry prognostic subtype of bladder cancer characterized by: enrichment of non-muscle-invasive patients and muscle-invasive patients with good prognosis, increased CREBBP/FGFR3/HRAS/NFE2L2 mutations, decreased intra-tumor heterogeneity and genome instability and activated tumor microenvironment.

show abstract

Essentials of bladder cancer worldwide: incidence, mortality rate and risk factors

Cited by 19 publications

References 71 publications

Epidemiological and Morphological Characteristics of Urothelial Bladder Cancer in a Bulgarian and a French Sample of Patients

Epidemiological and Morphological Characteristics of Urothelial Bladder Cancer in a Bulgarian and a French Sample of Patients

The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells

Racial differences in genomic features and new trans-ancestry prognosis subtypes in bladder cancer

Contact Info

Product

Resources

About